Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156



    MONTREAL, July 31 /CNW/ - Aegera Therapeutics Inc. is pleased to announce
the dosing of the first patient in a fifth phase 1 and 2 clinical oncology
study of AEG35156, a second generation antisense therapeutic targeting XIAP, a
key member of the Inhibitor of Apoptosis protein family.
    The study, made possible, in part, by funding from The Leukemia &
Lymphoma Society, is entitled "A Phase 1-2, Multicenter, Open-Label Study of
the X- Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients
with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic
Lymphoma and Follicular Lymphoma." It is being conducted at the Princess
Margaret Hospital (PMH) located in Toronto, Ontario, and is led by Principal
Investigator Dr. Christine Chen, with co-Principal Investigators Dr. Aaron
Schimmer and Dr. Joe Brandwein, all from the PMH's Department of Hematology
and Oncology.
    The primary objective of this study is to determine the recommended dose
of AEG35156 in patients with relapsed or refractory chronic lymphocytic
leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL),
and to determine the safety profile and response rate to AEG35156 in these
patient populations.
    "Preliminary evidence of activity in lymphoma was observed in phase 1
studies with AEG35156," stated Dr. Jacques Jolivet, Aegera's VP Clinical.
"This clinical trial will specifically study the role played by XIAP knockdown
in inducing antitumor activity in CLL, SLL and FL."
    "Our clinical program around AEG35156 continues to expand and broaden as
we seek to move this therapeutic forward to approval," added Aegera's
President and Chief Executive Officer, Dr. Michael J. Berendt.  "By adding
these lymphoma indications to AEG35156's ongoing phase 1 and 2 studies in
leukemia (AML), pancreatic, breast, and non-small cell lung cancer, we
continue to seek to position AEG35156 as an important therapeutic option that
could address important unmet medical needs across a spectrum of cancer
indications.  I must also thank, once again, The Leukemia & Lymphoma Society
for their financial support of this study which is the first funding granted
for a clinical trial under their new Therapy Acceleration Program."
    The Leukemia & Lymphoma Society Canada (LLSC) National Board Chairman,
Robert Rollwagen, added, "The initiation of patient enrollment and dosing in
Aegera's clinical trial marks an exciting time for lymphoma patients and LLSC.
We are pleased to help accelerate the testing of a new therapeutic option for
blood cancer patients and that Canadian lymphoma patients are among the first
to participate in this trial."
    
    About AEG35156
    
    Cancer cells acquire multiple mutations that disable their normal
response to apoptotic triggers. AEG35156, a second generation antisense which
targets XIAP, is designed to lower the apoptotic threshold of cancer cells,
enhancing their sensitivity to intrinsic death and chemotherapy, without
harming healthy cells. Aegera's published data with AEG35156, both in vitro
and in vivo, strongly supports this hypothesis, and validates XIAP as a novel
drug target for the development of anti-cancer therapeutics.
    
    About Aegera Therapeutics Inc.
    
    Aegera Therapeutics is a clinical stage biotechnology company focused on
developing drugs that control apoptosis to address major unmet medical needs.
In addition to AEG35156, Aegera has three additional programs in clinical
development for the treatment of cancer and neuropathic pain.  Details of
these programs can be found on Aegera's website at www.aegera.com.
    
    About The Leukemia & Lymphoma Society
    
    The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY,
with 68 chapters in the United States and Canada, is the world's largest
voluntary health organization dedicated to funding blood cancer research and
providing education and patient services. The LLS mission: Cure leukemia,
lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of
patients and their families. Since its founding in 1949, LLS has invested more
than $600 million in research specifically targeting leukemia, lymphoma and
myeloma. Last year alone, LLS made 5.1 million contacts with patients,
caregivers and healthcare professionals.
    For more information about blood cancer, visit www.LLS.org or call the
LLS Information Resource Center (IRC), a call center staffed by master's level
social workers, nurses and health educators who provide information, support
and resources to patients and their families and caregivers. IRC information
specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to
6 p.m. ET.

    
     For further information:
     Aegera Therapeutics Inc.
     Donald Olds, MSc, MBA
     Chief Operating Officer & CFO
     (514) 288-5532 (*)295
     Email: donald.olds@aegera.com

    




For further information:

For further information: Donald Olds, MSc, MBA, Chief Operating Officer
& CFO of Aegera Therapeutics Inc., +1-514-288-5532 *295,
donald.olds@aegera.com, Web Site: http://www.aegera.com, http://www.LLS.org

Organization Profile

AEGERA THERAPEUTICS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890